Racial And Sex Representation In Clinical Trials: Where Are We In Abdominal Organ Transplantation?

Clinical trials have historically failed to reflect the diversity of patients who may ultimately benefit from interventions being studied.1,2 Lack of diversity among trial participants can underestimate the effects of biological variation in treatment effect and further reduce equity and access to evidence-based healthcare for minority patients.3 The NIH and FDA implemented the Revitalization Act of 1993 to address these issues and provide guidelines to promote the inclusion of women and minorities in clinical trials.4.